Bead-Based Multiplex Genotyping of Human Papillomaviruses

ABSTRACT Typing of human papillomaviruses (HPV) by DNA hybridization procedures, such as reverse line blot (RLB) assay, is sensitive and well validated. However, the application of these assays to high-throughput analyses is limited. Here, we describe the development of multiplex human papillomavirus genotyping (MPG), a quantitative and sensitive high-throughput procedure for the identification of multiple high- and low-risk genital HPV genotypes in a single reaction. MPG is based on the amplification of HPV DNA by a general primer PCR (GP5+/6+) and the subsequent detection of the products with type-specific oligonucleotide probes coupled to fluorescence-labeled polystyrene beads (Luminex suspension array technology). Up to 100 different HPV types can be detected simultaneously with MPG, and the method is fast and labor saving. We detected all 22 HPV types examined with high specificity and reproducibility (the median interplate coefficient of variation was below 10%). Detection limits for the different HPV types varied between 100 and 800 pg of PCR products. We compared the performance of MPG to an established RLB assay on GP5+/6+-PCR products derived from 94 clinical samples. The evaluation showed an excellent agreement (kappa = 0.922) but also indicated a higher sensitivity of MPG. In conclusion, MPG appears to be highly suitable for large-scale epidemiological studies and vaccination trials as well as for routine diagnostic purposes.

[1]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[2]  M. Weiner,et al.  Fluorescent microsphere‐based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification , 2001, Human mutation.

[3]  H. Hausen Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[4]  B. Woda,et al.  Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays. , 2005, The Journal of molecular diagnostics : JMD.

[5]  P. Berger,et al.  Christianity and Democracy: The Global Picture , 2004 .

[6]  V. Moreno,et al.  Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study , 2002, The Lancet.

[7]  D. Higgins,et al.  T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.

[8]  P. Hillemanns,et al.  Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[10]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[11]  P. Snijders,et al.  POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women , 2004, International journal of cancer.

[12]  S. Dunbar,et al.  Microsphere suspension array technology for SNP detection in cattle , 2003, IEEE Engineering in Medicine and Biology Magazine.

[13]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[14]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[15]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[16]  Wim Quint,et al.  Development and Clinical Evaluation of a Highly Sensitive PCR-Reverse Hybridization Line Probe Assay for Detection and Identification of Anogenital Human Papillomavirus , 1999, Journal of Clinical Microbiology.

[17]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[18]  K. Zanotti,et al.  New cervical cancer screening strategy: combined Pap and HPV testing. , 2005, Cleveland Clinic journal of medicine.

[19]  J. Berkhof,et al.  Prevalence of types 16 and 33 is increased in high‐risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse , 2005, International journal of cancer.

[20]  S. Dunbar,et al.  Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system. , 2003, Journal of microbiological methods.

[21]  C. Meijer,et al.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. , 1995, The Journal of general virology.

[22]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[23]  A. Mazumder,et al.  Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping. , 2000, Cytometry.

[24]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[25]  M. Hakama,et al.  Comparison of HPV test versus conventional and automation‐assisted Pap screening as potential screening tools for preventing cervical cancer , 2004, BJOG : an international journal of obstetrics and gynaecology.

[26]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.